<DOC>
	<DOCNO>NCT00968929</DOCNO>
	<brief_summary>Recombinant streptokinase ( r-SK ) effective thrombolytic agent develop gene engineering . Its characteristic high output low production cost make affordable treat acute myocardial infarction ( AMI ) develop country . It unclear whether r-SK use patient pulmonary embolism ( PE ) . The aim study investigate efficacy safety 1.5 million IU r-SK 2 hour infusion 20,000 IU/kg urokinase ( UK ) 2 hour infusion select PE patient .</brief_summary>
	<brief_title>Recombinant Streptokinase Versus Urokinase Pulmonary Embolism China ( RESUPEC )</brief_title>
	<detailed_description>Pulmonary embolism ( PE ) common cardiovascular illness . Massive PE characterize cardiogenic shock and/or persistent arterial hypotension . Submassive PE patient define right ventricular dysfunction ( RVD ) identify echocardiography CT etc . The mortality massive submassive PE high low-risk PE . PE mortality rate &gt; 15 % first 3 month diagnosis . Thrombolytic treatment commence soon possible high-risk PE diagnose . Thrombolysis prove rapid effective therapy reduce obstruction pulmonary circulation normalize hemodynamic parameter . The ultimate goal thrombolytic therapy disease minimize early morbidity mortality prevent recurrence without provoke excessive bleeding . Currently , choice thrombolytic agent regimen ( SK , UK rt-PA ) mostly base personal regional preference . A novel dose regimen UK ( 3 million IU/2h , 4400 IU/kg load dose follow 4400 IU/kg/h 12h ) SK ( 1.5 million IU /2h ) recommend ESC guideline . Considering low body weight Chinese population , relative low dosage UK-2h ( 20,000 IU/kg ) regimen combine low molecular weight heparin ( LMWH ) use Chinese population . Our previous study reveal efficacy safety UK-2h ( 20 000 IU/Kg ) similar UK-12h ( standard regimen ) Chinese patient . Thus UK-2h ( 20,000 IU/Kg ) become popular alternative choice treat PE China low cost convenience . Natural streptokinase ( n-SK SK ) old thrombolytic agent . However , immunogenicity lower safety constitute concern among doctor . In recent year , development gene engineering , r-SK produce . R-SK advantage contain streptolysin streptodornase unlike streptococci-derived n-SK might make safe theoretically . For low cost , r-SK use treat AMI especially develop country . In study , efficacy safety r-SK ( 1.5 million IU/2h ) UK-2h ( 20 000U/Kg ) treat acute PE compare . The study conduct patient massive PE submassive PE . The clinical efficacy , emboli dissolve efficacy safety evaluate .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Streptokinase</mesh_term>
	<criteria>Symptomatic PTE confirm either CTPA high probability ventilationperfusion lung scanning ( V/Q scan ) . Presented hemodynamic instability ( systolic blood pressure &lt; 90 mmHg fall systolic blood pressure 40 mmHg least 15 min , cardiogenic shock ) associate RVD identify echocardiography CT . Symptoms deterioration le 14 day diagnosis . Active bleed spontaneous intracranial hemorrhage precede 6 month Major surgery , organ biopsy recent puncture noncompressible vessel precede 2 week Cerebral arterial thrombosis precede 2 month Gastrointestinal bleed precede 10 day Major trauma within past 15 day Neurosurgery ophthalmologic operation precede 1 month Uncontrolled hypertension ( systolic blood pressure &gt; 180 mmHg and/or diastolic blood pressure &gt; 110 mmHg ) Recent external cardiac resuscitation manoeuvre Platelet count &lt; 100,000/mm3 admission Pregnancy , puerperium lactation precede 2 week Infectious pericarditis endocarditis Severe hepatic kidney dysfunction Hemorrhagic retinopathy due diabetes A known bleeding disorder . Chronic thromboembolic pulmonary hypertension ( CTEPH ) without new pulmonary thromboembolism ( PTE ) Received streptokinase precede 6 month Infected streptococcus precede 1 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>pulmonary embolism</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>massive</keyword>
	<keyword>submassive</keyword>
	<keyword>recombinant streptokinase</keyword>
	<keyword>urokinase</keyword>
</DOC>